Synthesis and biological evaluation of penam sulfones as inhibitors of β-lactamases

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 8, 2005, Pages 2847-2858

  Phillips, Oludotun A ^a   Reddy, Andhe V N ^b   Setti, Eduardo L ^b   Spevak, Paul ^b   Czajkowski, David P ^b   Atwal, Herninder ^b   Salama, Sameeh ^b   Micetich, Ronald G ^b   Maiti, Samarendra N ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b NAEJA Pharmaceutical Inc   (Canada)

Author keywords

Antibacterial activity; Penam sulfones; Lactamase inhibitors; Lactamases

Indexed keywords

3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLIC ACID 3 [1 O (CARBOXYMETHYL)OXIME]DISODIUM 4,4 DIOXIDE; BACTERIAL ENZYME; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFOTAXIMASE; CEFTAZIDIME; CEPHALOSPORINASE; PENAM DERIVATIVE; PIPERACILLIN; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 ACETYLHYDRAZONE) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 BENZOYLHYDRAZONE) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 BENZYLOXYCARBONYLHYDRAZONE) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 HYDROXYLOXIME) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 O ALLYLOXIME) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 O ETHYLOXIME) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 O METHYLOXIME) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 O TERT BUTYLOXIME) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 SEMICARBAZONE) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 (1 THIOSEMICARBAZONE) 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O (2 HYDROXYETHYL)OXIME] 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O (CARBOXAMIDOMETHYL)OXIME] 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O (CYCLOPROPYLMETHYL)OXIME] 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O (METHOXYMETHYL)OXIME] 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O (TERT BUTYLOXYCARBONYLMETHYL)OXIME] 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O [(PIPERIDIN 2 YL)METHYL]OXIME] 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O [(PYRIDIN 2 YL)METHYL]OXIME] 4,4 DIOXIDE; SODIUM 3 FORMYL 3 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 3 [1 O [2 (1H 1,2,3 TRIAZOL 1 YL)ETHYL]OXIME] 4,4 DIOXIDE; SODIUM 3 METHYL 7 OXO 3 [N (2 OXO 1 IMIDAZOLIDINYL)FORMIMIDOYL] 4 THIA 1 AZABICYCLO[3.2.0]HEPTANE 2 CARBOXYLATE 4,4 DIOXIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; PSEUDOMONAS AERUGINOSA; SUBSTITUTION REACTION;

EID: 15244358821     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.02.020     Document Type: Article

References (26)

1. H.C. Neu The crisis in antibiotic resistance Science 257 1992 1064 1072
2. J.N. Samaha-Kfoury, and G.F. Araj Recent developments in β-lactamases and extended spectrum β-lactamases BMJ 327 2003 1209 1213
3. R.P. Ambler The structure of β-lactamases Philos. Trans. R. Soc. London, Ser. B 289 1980 321 331
4. B. Jaurin, and T. Gundstrom AmpC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of β-lactamases of the penicillinase type Proc. Natl. Acad. Sci. U.S.A. 78 1981 4897 4901
5. P. Lendent, X. Raquet, B. Joris, J. van Beeumen, and J.A. Frere Comparative study of class D β-lactamases Biochem. J. 292 1993 555 562
6. C.C. Sanders, and W.E.J. Sanders β-Lactam resistance in Gram-negative bacteria: global trends and clinical impact Clin. Infect. Dis. 15 1992 824 839
7. B. Di Giacomo, G. Tarzia, A. Bedini, G. Gatti, F. Bartoccini, C. Balsamini, A. Tontini, W. Baffone, E. Di Modugno, and A. Felici Synthesis of new C-6 alkyliden penicillin as β-lactamase inhibitors IL Farmaco 57 2002 273 283
8. C. Li, D.P. Nicolau, P.D. Lister, R. Quintiliani, and C.H. Nightingale Pharmacodynamic study of β-lactams alone and in combination with β-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible β-lactamase J. Antimicrob. Chemother. 53 2004 297 304
9. R. Sutherland β-Lactam/β-lactamase inhibitor combinations: development, antibacterial activity and clinical applications Infections 23 1995 191 200
10. L.A. Miller, K. Ratnam, and D.J. Payne β-Lactamase inhibitor combinations in the 21st century: current agents and new developments Curr. Opin. Pharmacol. 1 2001 451 458
11. N. Lee, K.-Y. Yuen, and C.R. Kumana Clinical role of β-lactam/ β-lactamase inhibitor combination Drugs 63 14 2003 1511 1524
12. D.M. Livermore Determinants of the activity of β-lactamase inhibitors combinations J. Antimicrob. Chemother. 31 Suppl A 1993 9 21
13. K. Bush, C. Macalintal, B.A. Rasmussen, V.J. Lee, and Y. Yang Kinetic interactions of tazobactam with β-lactamases from all major structural classes Antimicrob. Agents Chemother. 37 1993 851 858
14. D.M. Livermore Clinical significance of β-lactamase induction and stable derepression on Gram-negative rods Eur. J. Clin. Microbiol. 6 1987 439 445
15. P.M. Bennett, and I. Chopra Molecular basis of β-lactamase induction in bacteria Antimicrob. Agents Chemother. 37 1993 153 158
16. N.D. Hanson, and C.C. Sanders Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae Curr. Pharm. Des. 5 1999 881 894
17. S. Trepanier, J.R. Knox, N. Clairoux, F. Sanschagrin, R.C. Levesque, and A. Huletsky Structure-function studies of Ser-289 in the class C β-lactamase from Enterobacter cloacae P99 Antimicrob. Agents Chemother. 43 1999 543 548
18. D.M. Livermore β-Lactamases in laboratory and clinical resistance Clin. Microbiol. Rev. 8 1995 557 584
19. H.G.F. Richter, P. Angehrn, C. Hubschwerlen, M. Kania, M.G.P. Page, J.-L. Specklin, and F.K. Winkler Design, synthesis and evaluation of 2β-alkenyl penam sulfone acids as inhibitors of β-lactamases J. Med. Chem. 39 1996 3712 3722
20. E.L. Setti, A.V.N. Reddy, O.A. Phillips, D.P. Czajkowski, K. Atchison, H. Atwal, R.G. Micetich, and S.N. Maiti Synthesis and β-lactamase inhibitory activity of 2β-alkoxycarbonyl penicillanic acid sulfones J. Antibiot. 49 9 1996 944 946
21. R.G. Micetich, S.N. Maiti, P. Spevak, M. Tanaka, T. Yamazaki, and K. Ogawa Synthesis of 2β-azidomethylpenicillanate-1,1-dioxides and 3-β-azido-3α-methyl-cepham-1,1-dioxides Synthesis 1986 292 296
22. D.O. Spry 2β-(Hydroxymethyl)penicillin J. Org. Chem. 44 17 1979 3084 3086
23. A.J. Wright The penicillins Mayo Clin. Proc. 74 1999 290 307
24. S.G.B. Amyes Genes and spectrum Clin. Infect. Dis. 27 Suppl 1 1998 S21 S28
25. E.L. Setti, C. Fiakpui, O.A. Phillips, D.P. Czajkowski, K. Atchison, R.G. Micetich, and S.N. Maiti Chemical modification of tazobactam synthesis of 2β-[(4-substituted)-1,2,3-triazol-1-yl]methyl penicillanic acid sulfone derivatives J. Antibiot. 48 11 1995 1320 1329
26. K. Bush, and R.B. Sykes Methodology for the study of β-lactamases Antimicrob. Agents Chemother. 30 1 1986 6 10